このエントリーをはてなブックマークに追加
ID 32861
JaLCDOI
フルテキストURL
著者
Ashizawa, Tatsuto Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Iwahori, Tohru Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Yokoyama, Takayoshi Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Kihara, Yuu Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Konnno, Osamu Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Jyojima, Yoshimaro Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Akashi, Isao Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Nakamura, Yuuki Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Hama, Kouichirou Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Iwamoto, Hitoshi Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Segawa, Mai Department of Surgery, Hachioji Medical Center of Tokyo Medical University
Takeuchi, Hironori Department of Practical Pharmacy, Tokyo University of Medical University Pharmacy and Life Science
Hirano, Toshihiko Department of Clinical Pharmacology, Tokyo University of Medical University Pharmacy and Life Science
Nagao, Takeshi Department of Surgery, Hachioji Medical Center of Tokyo Medical University
抄録

We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis patients with gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such patients. For comparison, the same parameters were also investigated in 10 cancer patients not undergoing dialysis. Items investigated included (1) plasma concentrations of SN-38, SN-38G and CPT-11 at 0, 1, 12, 24, 36, 48 and 72h after administration, together with a comparison of mean AUC values for 3 dose levels of CPT-11 (50, 60 and 70mg/m2) in dialysis patients and controls;and (2) occurrence of adverse events. Several findings emerged from this study:(1) No significant difference was observed in the AUC for SN-38 or CPT-11 between the dialysis and control groups;(2) The AUC for SN-38G at each dose was significantly higher in dialysis patients;and (3) Grade 1-4 leucopenia was observed in 11 of the dialysis patients. One patient developed grade 4 leucopenia and died due to sepsis. Anorexia, diarrhea, nausea, alopecia and interstitial pneumonia occurred in 6 dialysis patients. We found changes in drug dispositions of CPT-11, SN-38 and SN-38G in dialysis patients, suggesting that hepatic excretion, especially that of SN-38G, was increased. No significant difference in occurrence of adverse events was observed between the 2 groups. This indicates that CPT-11 can be administered safely in patients on dialysis.

キーワード
irinotecan hydrochloride (CPT-11)
chronic kidney disease (CKD)
end-stage renal disease (ESRD)
dialysis
colorectal cancer
Amo Type
Original Article
発行日
2010-02
出版物タイトル
Acta Medica Okayama
64巻
1号
出版者
Okayama University Medical School
開始ページ
19
終了ページ
26
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT